Search

for
Search:

Community Join

5 / 209 results

community Pelage PP405: New Hair Growth from Inactive Follicular Units - Phase 2a results at AAD 2026

1080 upvotes 5 months ago

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

community Pelage PP405 Phase 2a completed.

61 upvotes 7 months ago

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

community I think we should all keep an eye out for Pelage PP405. February 2025 will be interesting.

118 upvotes 1 year ago

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march

30 upvotes 5 months ago

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026

122 upvotes 5 months ago

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

View more "pelage pp405" in community →

Learn

1 / 801 results

learn PP405

mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

Got small bald patches they say are from stress? PP405 sprays could help bring them back to life. PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier; its registered Phase 2 trial (NCT06393452) tested it once daily in 78 adults with pattern hair loss, for safety and tolerability. It is not approved, not for sale, and has not been studied in alopecia areata or stress-related shedding.
Can applying a mask with PP405 directly to thinning areas give your scalp the push it needs? No PP405 mask exists to test: PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, it is not an anti-DHT ingredient, and it is not on sale. Its registered Phase 2 trial (NCT06393452) measured safety, not regrowth, and a rinse-out mask is in any case the wrong format for reaching the follicle.
Did you know PP405 peptides can help protect your follicles from DHT? PP405 is not a peptide and does not block DHT: it is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, aimed at waking dormant follicles. Its registered Phase 2 trial (NCT06393452) measured safety and tolerability in 78 adults with pattern hair loss; it is not approved and not for sale.

View more "pelage pp405" in learn →

Research

5 / 1000+ results

research PP405 in Alopecia: An Emerging Molecule worth Investigating

January 2026 in “Journal of Community Medicine and Health Solutions”

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

research LB1045 Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo

July 2024 in “Journal of Investigative Dermatology”

PP405 may help hair growth by activating hair follicle stem cells.

New Therapeutics in the Management of Androgenetic Alopecia

research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

research Hair Melanin and Hair Color

35 citations , January 1981

research Recent Advances in Drug Development for Hair Loss

April 2025 in “International Journal of Molecular Sciences”

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

View more "pelage pp405" in research →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →